Data gathered: May 31
Alternative Data for Alzamend Neuro
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 80 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 514 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,825 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Alzamend Neuro
None
| Price | $3.83 |
| Target Price | Sign up |
| Volume | 2,010,000 |
| Market Cap | $4M |
| Year Range | $3.29 - $15.93 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Alzamend Neuro doses first patient in Phase II study of AL001May 29 - Thefly.com |
 |
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General HospitalMay 28 - Yahoo |
 |
Alzamend Neuro (NASDAQ:ALZN) Trading Down 5.5% – Here’s What HappenedMay 27 - ETF Daily News |
 |
Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human ParticipantsMay 13 - Biztoc.com |
|
Alzamend Neuro announces 1-for-9 reverse stock splitMay 8 - Thefly.com |
|
Alzamend Neuro partners with Mint Labs to support five upcoming trialsMay 7 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 0 | 0 | 0 | -1M | -1M | -1.710 |
| Q4 '24 | 0 | 0 | 0 | -1.4M | -1.3M | -3.600 |
| Q3 '24 | 0 | 13,000 | -13,000 | -970,000 | -950,000 | -1.250 |
| Q2 '24 | 76,000 | 13,000 | 63,000 | -850,000 | -840,000 | -13.350 |
| Q1 '24 | 0 | 13,000 | -13,000 | -2.7M | -2.6M | -0.380 |
Insider Transactions View All
| AULT MILTON C III filed to sell 1,843 shares at $5.3. May 14 '25 |
| AULT MILTON C III filed to sell 8,260 shares at $5.1. May 14 '25 |
| Horne William B. filed to buy 30,000 shares at $1. March 27 '25 |
| Katzoff David J filed to buy 5,540 shares at $1. March 24 '25 |
| AULT MILTON C III filed to buy 85,273 shares at $1. March 25 '25 |
Similar companies
Read more about Alzamend Neuro (ALZN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Alzamend Neuro?
The Market Cap of Alzamend Neuro is $4M.
What is the current stock price of Alzamend Neuro?
Currently, the price of one share of Alzamend Neuro stock is $3.83.
How can I analyze the ALZN stock price chart for investment decisions?
The ALZN stock price chart above provides a comprehensive visual representation of Alzamend Neuro's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Alzamend Neuro shares. Our platform offers an up-to-date ALZN stock price chart, along with technical data analysis and alternative data insights.
Does ALZN offer dividends to its shareholders?
As of our latest update, Alzamend Neuro (ALZN) does not offer dividends to its shareholders. Investors interested in Alzamend Neuro should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Alzamend Neuro?
Some of the similar stocks of Alzamend Neuro are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.